Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Allogene Therapeutics (ALLO) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Allo-329, CyclophophamideLupus Nephritis, Systemic Sclerosis, Systemic Lupus Erythematosus (With And Without Nephritis), Idiopathic Inflammatory MyopathyPhase IRecruitingA Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseJul 08, 2025―
Cyclophosphamide, Fludarabine, Cemacabtagene Ansegedleucel, Foresight Clarity™ Iuo Mrd Test, Powered By Phased-Seq™Large B-Cell LymphomaPhase IIRecruitingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLJun 26, 2024
Cyclophosphamide, Fludarabine, Allo-647, Allo-501ARelapsed/Refractory Large B Cell LymphomaPhase IIActive Not RecruitingEvaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyDec 08, 2022―
Cyclophosphamide, Fludarabine, Allo-647, Allo-605Relapsed/Refractory Multiple Myelomaphase1AndPhase2TerminatedSafety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaAug 04, 2021―
Cyclophosphamide, Fludarabine, Allo-647, Allo-316Advanced/Metastatic Clear Cell Renal Cell CarcinomaPhase IRecruitingSafety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaJan 04, 2021―
Cyclophosphamide, Fludarabine, Allo-647, Allo-501ARelapsed Or Refractory Large B Cell Lymphoma, Relapsed Or Refractory Chronic Lymphocytic Leukemia, Relapsed Or Refractory Small Lymphocytic Lymphomaphase1AndPhase2Active Not RecruitingSafety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)May 29, 2020―
Cyclophosphamide, Nirogacestat, Fludarabine, Allo-715, Allo-647Relapsed/Refractory Multiple MyelomaPhase IActive Not RecruitingSafety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)Sep 16, 2019―
Cyclophosphamide, Fludarabine, Allo-647, Allo-501Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Large B Cell LymphomaPhase IActive Not RecruitingSafety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaApr 04, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Allogene Therapeutics (ALLO) have in its pipeline
Allogene Therapeutics ALLO is currently developing the following drugs: Allo-329, Cyclophophamide, Cyclophosphamide, Fludarabine, Cemacabtagene Ansegedleucel, Foresight Clarity™ Iuo Mrd Test, Powered By Phased-Seq™, Cyclophosphamide, Fludarabine, Allo-647, Allo-501A, Cyclophosphamide, Fludarabine, Allo-647, Allo-605, Cyclophosphamide, Fludarabine, Allo-647, Allo-316, Cyclophosphamide, Nirogacestat, Fludarabine, Allo-715, Allo-647, Cyclophosphamide, Fludarabine, Allo-647, Allo-501. These drug candidates are in various stages of clinical development as the company works toward FDA approval.